Santo develops next‑generation in‑vivo gene therapies using advanced lentiviral vector technology. The company focuses on rare diseases and oncology, creating fifth‑generation lentiviral vectors that aim for a single administration to achieve lifelong cures, with a pipeline targeting neurofibromatosis, meningioma, and malignant mesothelioma.
Funding
Funding not disclosed
Founders
Product
Problem
Current gene therapy approaches often rely on ex vivo manipulation or first‑generation viral vectors that can present safety concerns, limited tissue targeting, and require multiple dosing, restricting their applicability for rare diseases and hard‑to‑treat cancers.
Solution
Santo develops in vivo gene therapies using a fifth‑generation lentiviral vector platform designed for safe, efficient delivery of therapeutic genes directly to patient tissues. The platform incorporates advanced vector engineering, gene‑editing capabilities, and serum‑free production methods to enhance potency while reducing immunogenicity and manufacturing complexity. By enabling a single administration that can provide durable therapeutic expression, Santo aims to deliver lifelong cures for rare genetic disorders and high‑unmet‑need oncology indications such as neurofibromatosis, meningioma, and malignant mesothelioma. The company’s integrated model combines high‑throughput vector screening, serum‑free bioprocessing, and disease‑focused preclinical models to accelerate development timelines.
Target Audience
Primary customers are pharmaceutical and biotech companies developing gene‑based treatments for rare genetic diseases and oncology, as well as academic research groups seeking advanced lentiviral vectors for in vivo studies.
Features
- Fifth‑generation lentiviral vectors with improved safety profiles and tissue‑specific tropism
- In vivo delivery eliminates the need for ex vivo cell manipulation and multiple dosing regimens
- Integrated gene‑editing tools enable precise genomic modifications for disease correction
- Serum‑free, high‑throughput vector production platform that enhances scalability and reduces contamination risk
- High‑throughput screening pipeline for rapid optimization of vector designs and therapeutic payloads
- Preclinical disease models tailored to rare genetic disorders and oncology targets to streamline translational studies